Last reviewed · How we verify

NCT05331716: LAVAONLY

Modification of the Local Abnormal Ventricular Activity Only

Completed Last updated 7 October 2022
What this trial tests

trial testing Cardiac ablation therapy in Ventricular Tachycardia in 22 participants. Completed in 31 December 2021.

Timeline
1 January 2019
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorUniversity of Kiel
StatusCompleted
Study typeOBSERVATIONAL
Enrollment22
Start date1 January 2019
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University of Kiel

Who can join

18 and older, any sex, with Ventricular Tachycardia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Local abnormal ventricular activity (LAVA) is composed of high-frequency, mainly low voltage signals that represent near-field signals from slow-conducting tissue and thus potential VT isthmuses. The identification of LAVA potentials and their modification have usually been a complimentary component of the substrate-based modification of scar related ventricular arrhtyhmias. With better identification through technical solutions and improved algorithms, LAVA modification may be feasible for treatment in therapy refractory VT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ventricular Tachycardia

Currently open trials in the same condition.

Other University of Kiel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05331716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing